[Clinical end-points and surrogate markers of pulmonary arterial hypertension in the light of evidence-based treatment].
Pulmonary arterial hypertension (PAH) is a rare, fatal and progressive disease. There is an acceleration in the advent of new therapies in parallel to the development of the knowledge about etiogenesis and pathogenesis of PAH. Therefore, to optimize the goals of PAH-specific treatment and to determine the time to shift from monotherapy to combination therapy, simple, objective and reproducible end-points, which may predict the disease severity, progression rate and life expectancy are needed. The adventure of end points in PAH has started with six minute walk distance and functional capacity, and continues with new parameters (biochemical marker, time to clinical worsening, echocardiography and magnetic resonance imaging etc.), which can better reflect the clinical outcome.
Can
Mehmet Mustafa
MM
Kartal Koşuyolu Yüksek Ihtisas Eğitim ve Araştirma Hastanesi, Kardiyoloji Kliniği, Istanbul, Türkiye.
Kaymaz
Cihangir
C
D015415:Biomarkers / Q000097:blood; D018450:Disease Progression; D019317:Evidence-Based Medicine; D005080:Exercise Test; D065627:Familial Primary Pulmonary Hypertension; D006439:Hemodynamics; D006801:Humans; D006976:Hypertension, Pulmonary / Q000097:blood / Q000188:drug therapy / Q000401:mortality / Q000473:pathology; D008017:Life Expectancy; D012129:Respiratory Function Tests; D012720:Severity of Illness Index
D015415:Biomarkers